Efficacy of recombinant human erythropoietin therapy started one month after autologous peripheral blood stem cell transplantation.
On day 30 after autologous peripheral blood stem cell transplantation (PBSCT), 20 patients were randomized to receive either erythropoietin at a dose of 500 U/kg/week s.c. (Epo group) or no treatment (control group). After 3 weeks, hemoglobin (p<0.0001) and serum transferrin receptor (p<0.0001) concentrations were higher in the Epo group. Hb response (+2 g/dL) was achieved in 100% vs 28% (p<0.0001) and Hb correction (> or =13 g/dL) in 70% vs 10% (p=0.0238) of the patients, respectively. This is the first randomized study showing an efficacy of erythropoietin therapy on Hb levels after autologous PBSCT.
Vanstraelen
Gaëtan
G
Baron
Frédéric
F
Frère
Pascale
P
Hafraoui
Kaoutar
K
Fillet
Georges
G
Beguin
Yves
Y
D000368:Aged; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006402:Hematologic Diseases / Q000097:blood / Q000601:surgery*; D006801:Humans; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods; D011994:Recombinant Proteins; D014182:Transplantation, Autologous
D011994:Recombinant Proteins; D004921:Erythropoietin